Effects of Campomanesia xanthocarpa on inflammatory processes, oxidative stress, endothelial dysfunction and lipid biomarkers in hypercholesterolemic individuals

• Published in: Atherosclerosis Vol. 234; no. 1; pp. 85 - 92
• Main Authors: Viecili, Paulo Ricardo Nazário, Borges, Diego Olschowsky, Kirsten, Karina, Malheiros, Jênifer, Viecili, Eduardo, Melo, Rodolfo Dahlem, Trevisan, Gabriela, da Silva, Mariane Arnoldi, Bochi, Guilherme Vargas, Moresco, Rafael Noal, Klafke, Jonatas Zeni
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier Ireland Ltd 01.05.2014
• Subjects: Advanced oxidation protein products; Biomarkers - blood; C-reactive protein; Cardiovascular; Cholesterol - blood; Double-Blind Method; Endothelium, Vascular - drug effects; Endothelium, Vascular - physiopathology; Female; Humans; Hypercholesterolemia; Hypercholesterolemia - blood; Hypercholesterolemia - drug therapy; Inflammation - drug therapy; Ischemia-modified albumin; Male; Medicinal plant; Middle Aged; Myrtaceae; Oxidative Stress - drug effects; Phytotherapy; Plant Extracts - pharmacology; Plant Extracts - therapeutic use; Triglycerides - blood; Ischemia-modified albumin; Myrtaceae; C-reactive protein; Hypercholesterolemia; Advanced oxidation protein products; Medicinal plant
• ISSN: 0021-9150; 1879-1484
• DOI: 10.1016/j.atherosclerosis.2014.02.010

Abstract In Brazil, the edible plant Campomanesia xanthocarpa Berg. (Myrtaceae), popularly known as “guavirova,” has been studied in hypercholesterolemic individuals. The present work investigated the effects of C. xanthocarpa on inflammatory processes, oxidative stress, endothelial dysfunction and lipid biomarkers in hypercholesterolemic individuals. A total of 156 individuals were selected in a double-blind fashion and randomly divided into two groups in accordance with the intervals used in the criteria for hypercholesterolemia: individuals with total cholesterol (TC) levels between 200 and 240 mg/dL (undesirable level individuals – UL) and individuals with TC levels >240 mg/dL (hypercholesterolemic individuals – HL). Both groups had a control group (CG), which received placebo treatment, an encapsulated excipient group (lactose) and an experimental group that received 500 mg (EG 500), 750 mg (EG 750) or 1000 mg (EG 1000) of encapsulated C. xanthocarpa . The inflammatory processes (high-sensitivity C-reactive protein – hs-CRP), oxidative stress (advanced oxidation protein products–AOPPs; ischemia-modified albumin–IMA), endothelial dysfunction (nitric oxide – NOx) and biochemical (TC, triglycerides, high-density lipoprotein – HDL, low-density lipoproteins – LDL, and very low-density lipoprotein – VLDL) parameters were measured before and 90 days after the initiation of treatment. A significant decrease in TC and LDL levels was observed in HL individuals from the EG 500 group (reduction of 29 ± 3% and 41 ± 5% to levels before treatment) compared to the CG group individuals. A significant reduction in oxidative stress and inflammatory process components (reduction of 52 ± 11% in AOPPs, 32 ± 10% in IMA and 57 ± 7% in hs-CRP) and a significant increase in NOx (increase of 84 ± 27%) was observed in HL individuals in the EG 1000 group when compared to the CG group individuals. Treatment with encapsulated C. xanthocarpa reduced blood TC and LDL levels in hypercholesterolemic individuals. In addition to its effect on cholesterol levels, this plant reduced oxidative stress in hypercholesterolemic individuals and improved the levels of NOx.